Houston, TX, (August 2, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announces today publication in the August 2005 issue of the American Society of Microbiology journal, Antimicrobial Agents and Chemotherapy of the results of studies conducted by Dr. Xin-Xing Tan, CytoGenix Senior Scientist and Dr. Jeffrey K. Actor, Associate Professor in the department of Pathology and Laboratory Medicine, University of Texas Medical School.
The paper titled "Peptide Nucleic Acid Antisense Oligomer as a Therapeutic Strategy against Bacterial Infection: Proof of Principle Using Mouse Intraperitoneal Infection", demonstrates that one of the company's antimicrobial compounds is highly effective in reducing bacterial load and inflammatory products associated with sepsis in a mouse infection model.
Dr. Malcolm Skolnick, Chairman/CEO commented, "This latest publication from the Company's laboratory represents an important step in our long term plan for the application of our technology in the treatment of infectious diseases. Application of genetic techniques in disease control is the future of medicine and our mission at CytoGenix is to bring this technology from the laboratory to the clinic". Dr. Skolnick adds, "We are encouraged and pleased that our peers in the international medical research community continue to recognize and validate our efforts."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (800) 677-5707
